Novo Medi Sciences Pvt. Ltd. has launched Nexipox Plus, a next-generation varicella (chickenpox) vaccine developed specifically for Indian clinical and operational conditions.
The company positions Nexipox Plus as the first proactive upgrade of varicella vaccine designed for India, addressing stability, safety, and immunogenicity challenges seen in real-world use.
Why varicella vaccines need formulation innovation?
Live attenuated varicella vaccines are thermolabile, meaning they are sensitive to heat. This makes stability and potency retention critical, especially in countries with:
- Hot climates
- Variable cold-chain infrastructure
- High patient volumes
Nexipox Plus introduces a 2X trehalose-based stabiliser system to improve formulation robustness.
What makes Nexipox Plus different?
The vaccine replaces conventional stabilisers such as gelatin and mannitol with trehalose. This shift delivers several advantages:
- Enhanced viral stability
- Better potency preservation
- Reduced risk of allergic reactions
- Lower chance of antigen crystallisation
The result is more consistent vaccine performance during storage, transport, and administration.
Clinical data shows strong immune response
Clinical studies in Indian patients demonstrated:
- 98% seroconversion after a two-dose schedule
- 35.4-fold geometric mean rise in antibody titres
“These results indicate a robust immune response and effective protection,” said Forum Bhagat, Managing Director, Novo Medi Sciences.
Favourable safety profile
In comparative clinical trials:
- No serious adverse events were causally linked to Nexipox Plus
- Removal of gelatin further supports improved tolerability
This strengthens its suitability for routine immunisation.
Expert perspective on clinical relevance
Dr Nitin K. Shah, Consultant Paediatrician and Paediatric Hemato-Oncologist, Mumbai, highlighted:
- Enhanced immunogenicity as the key clinical advance
- More consistent immune responses due to improved formulation
- Increased clinician confidence in routine practice
Supporting India’s immunisation priorities
Chickenpox remains prevalent in India. Nexipox Plus is designed to support:
- Higher vaccination compliance
- Affordable and scalable deployment
- Adoption in private and institutional settings
The vaccine is approved by DCGI for use from 12 months of age.
Built for future global expansion
Nexipox Plus is backed by patented technology across 156 countries. Novo Medi Sciences is evaluating international expansion based on:
- Public health need
- Sustainable supply planning
Bottom line
With Nexipox Plus, Novo Medi Sciences advances formulation-led vaccine innovation, delivering improved stability, safety, and immunogenicity tailored to Indian healthcare realities.
